Overview
- The case stems from a 2023 St. Louis verdict awarding $1.25 million to plaintiff John Durnell for Bayer’s failure to warn about alleged cancer risks.
- The U.S. Solicitor General urged the Court to grant review, signaling federal interest in settling the preemption question.
- Arguments are expected in the spring with a decision likely by June or early July based on the Court’s usual schedule.
- Bayer reports about 197,000 registered Roundup claims, says roughly 132,000 have been settled or did not meet criteria, and has spent or reserved more than $10 billion.
- Bayer CEO Bill Anderson welcomed the review as a step toward regulatory clarity, while advocacy groups warned a pro-preemption ruling could limit access to state juries.